Stacey J. Wieczorek

Biological variation for N-Terminal Pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure

Alan H.B. Wu, Andrew M. Smith, Stacey J. Wieczorek et al. · The American Journal of Cardiology · 2003 · 257 citations

Heart Failure, Cardiovascular Disease, Therapeutic Monitoring +9

A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: A multicenter evaluation

Stacey J. Wieczorek, Alan H.B. Wu, Robert H. Christenson et al. · American Heart Journal · 2002 · 178 citations

Cardiomyopathy, Heart Failure, Cardiovascular Disease +10

Evolution of Enzymatic Activities in the Enolase Superfamily:  Identification of a “New” General Acid Catalyst in the Active Site of <scp>d</scp>-Galactonate Dehydratase from <i>Escherichia coli</i>

Stacey J. Wieczorek, Kathryn A. Kalivoda, James G. Clifton et al. · Journal of the American Chemical Society · 1999 · 32 citations

Enolase Superfamily, Biosynthesis, Enzymatic Activities +14

Correlation of B-type natriuretic peptide level to 6-min walk test performance in patients with left ventricular systolic dysfunction

Stacey J. Wieczorek, David Hager, Mary-Beth Barry et al. · Clinica Chimica Acta · 2003 · 21 citations

Heart Failure, Cardiovascular Disease, Cardiovascular Function +4

Prognostic Value of the Ortho Vitros Cardiac Troponin I Assay in Patients With Symptoms of Myocardial Ischemia

Fred S. Apple, MaryAnn M Murakami, Heidi H. Quist et al. · American Journal of Clinical Pathology · 2003 · 16 citations

Myocardial Ischemia, Cardiovascular Toxicity, Risk Assessment Value +20